Published Paper Details:

Breast cancer is a major global health challenge, and natural products offer promising avenues for novel therapeutics. This study evaluated the in-vitro anticancer activity of ethanolic crude extracts of Trigonella foenum-graecum (fenugreek) leaves against MCF-7 human breast cancer cells, complemented by in-silico docking and ADMET analyses. GC-MS profiling identified key phytoconstituents including ricinoleic acid, elaidic acid, isolinoleic acid, stearic acid, azelaic acid, phytol, and squalene, most of which exhibited favorable drug-likeness and low predicted toxicity. MTT assays revealed dose-dependent inhibition of MCF-7 proliferation, with cell viability decreasing from 57.6% at 250 ?g/ml to 16.8% at 500 ?g/ml, corresponding to inhibition rates of 42.4% and 83.2%, respectively. In-silico docking suggested strong binding affinities of azelaic acid, elaidic acid, and ricinoleic acid to cancer-related targets, potentially mediating apoptosis and metabolic disruption. These findings indicate that fenugreek leaves possess significant anticancer potential, warranting further mechanistic and in-vivo studies for therapeutic development.